Phase 2 × Osteosarcoma × Dermatologic × Clear all
NCT04284774 2025-12-04

Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial

National Cancer Institute (NCI)

Phase 2 Active not recruiting
5 enrolled 9 charts
NCT00445965 2024-04-04

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
78 enrolled 11 charts
NCT00154388 2016-11-18

Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

Novartis

Phase 2 Completed
185 enrolled